Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Use of emboli-blocking filters increases, but rigorous data are lacking

Article Abstract:

The controversial practice of the lifelong anticoagulation therapy that is generally prescribed for patients who receive Inferior Vena Cava (IVC) filters posing an enduring risk of bleeding is presented. The prospect of lifelong anticoagulation and other possible complications of a permanent device led to the development of retrievable IVC filters which are intended to prevent fatal pulmonary embolism during high-risk events but allow for their subsequent removal.

Author: Brenden, Erin
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2006
Complications and side effects, Implants, Artificial, Prostheses and implants, Prosthesis, Vena cava, Venae cavae

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Duration of anticoagulation following venous thromboembolism: A meta analysis

Article Abstract:

The study aims to review that available evidence and quantify the risks and benefits of extending the duration of anticoagulation in patients with venous thromboembolism (VTE). The findings indicate that patients who receive extended anticoagulation are protected form recurrent VTE while receiving long-term therapy and it is concluded that clinical benefit is maintained after anticoagulation is discontinued, but the magnitude is less pronounced.

Author: Fein, Alan, Ost, David, Tepper, Josh, Mihara, Hanako, Lander, Owen, Heinzer, Raphael
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
Thromboembolism

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Agents to control bleeding show promise

Article Abstract:

Several clinical trials are being conducted to develop novel therapies to prevent bleeding in individuals at high risk of venous thrombolism who are treated with anticoagulant therapy as well as in patients with thrombocytopenia. Among the new treatments that show considerable potential are idraparinux injections, and an oral anticoagulant, which is a thrombin inhibitor known as dabigatran etexilate.

Author: Hampton, Tracy
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2007
Risk factors, Drug therapy, Thrombophlebitis, Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Care and treatment, Research, United States, Anticoagulants (Medicine), Anticoagulants, Health aspects
Similar abstracts:
  • Abstracts: Medicare pay is changing; primary care will see increases, but surgical specialties face cuts. Use of physicians' services under medicare's resource - based payments
  • Abstracts: Outsourcing clinical trials to India rash and risky, critics warn. Newly expanded European Union faces growing pains
  • Abstracts: Managing lipid levels in diabetes beneficial but requires clinical judgment
  • Abstracts: Childhood vaccination and nontargeted infectious disease hospitalization. Timeliness of childhood vaccinations in the United States
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.